9-(2-脱氧-2-氟-beta-D-阿拉伯糖呋喃基)-2-氟-9H-嘌呤-6-胺 | 134217-15-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 中文名称: 9-(2-脱氧-2-氟-beta-D-阿拉伯糖呋喃基)-2-氟-9H-嘌呤-6-胺
• 英文名称: 2-fluoro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purin-6-amine
• 英文别名: 2-fluoro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine；2'-deoxy-2'-fluoro-β-2-fluoro-D-adenosine；2-fluoro-9-(2-fluoro-β-D-arabinosyl)adenine；6-Amino-2-fluoro-9-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)-9H-purine；(2R,3R,4S,5R)-5-(6-amino-2-fluoropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
• CAS: 134217-15-5
• 化学式: C₁₀H₁₁F₂N₅O₃
• 分子量: 287.226
• InChiKey: OOSVZNYQTCFEON-AYQXTPAHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  119
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  9-(2-脱氧-2-氟-beta-D-阿拉伯糖呋喃基)-2-氟-9H-嘌呤-6-胺 在 Jones reagent 、 silica gel 作用下， 以 丙酮 为溶剂， 生成 (2S,3R,4S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-4-fluoro-3-hydroxytetrahydrofuran-2-carboxylic acid
  参考文献：
  名称：

  [EN] METHODS OF TREATING MEDICAL CONDITIONS AND INHIBITING LINE1 REVERSE TRANSCRIPTASE USING A SUBSTITUTED 4-FLUORO-2,5-DIHYDROFURANYL PHOSPHONIC ACID OR RELATED COMPOUND
  [FR] MÉTHODES DE TRAITEMENT D'ÉTATS MÉDICAUX ET D'INHIBITION DE LA TRANSCRIPTASE INVERSE DE LA LINE1 À L'AIDE D'UN ACIDE 4-FLUORO-2,5-DIHYDROFURANYLE PHOSPHONIQUE SUBSTITUÉ OU D'UN COMPOSÉ APPARENTÉ

  摘要：

  The invention provides methods and compositions for treating medical disorders, such as cancer, and inhibiting LINE1 reverse transcriptase and/or HERV-K reverse transcriptase using a substituted 4-fluoro-2,5-dihydrofuranyl phosphonic acid or related compound.

  公开号：

  WO2022245814A1
• 作为产物：
  描述：

  2’-deoxy-2’-fluoro-3’,5’-di-O-benzoyl-β-2-fluoro-D-adenosine 在 甲醇 、 sodium methylate 作用下， 生成 9-(2-脱氧-2-氟-beta-D-阿拉伯糖呋喃基)-2-氟-9H-嘌呤-6-胺
  参考文献：
  名称：

  EP3862004

  摘要：

  公开号：

文献信息

• Anti-viral nucleosides
  申请人：Martin Armstrong Joseph

  公开号：US20060040890A1

  公开（公告）日：2006-02-23

  4-Amino-1-((2R,3S,4S,5R)-5-azido-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)- 1 H-pyrimidin-2-one (I:R 1 =R 2 =R 3 =R 4 =H) and prodrugs thereof are hepatitis C(HCV) polymerase inhibitors. Also disclosed are compositions and methods for inhibiting HCV and treating HCV-mediated diseases, processes for making the compounds and synthetic intermediates employed in the process.

  4-氨基-1-((2R,3S,4S,5R)-5-偶氮基-3,4-二羟基-5-羟甲基-四氢呋喃-2-基)-1H-嘧啶-2-酮（I:R1=R2=R3=R4=H）及其前药是丙型肝炎病毒（HCV）聚合酶抑制剂。还公开了用于抑制HCV和治疗HCV介导的疾病的组合物和方法，以及用于制备这些化合物和用于该过程中使用的合成中间体的方法。
• NUCLEOSIDE PHOSPHONATE DERIVATIVES
  申请人：Or Yat Sun

  公开号：US20090274686A1

  公开（公告）日：2009-11-05

  The present invention discloses compounds of formula (I) or (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral/anti-proliferative compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral infection in a subject in need of such therapy with said compounds.

  本发明揭示了化合物的公式(I)或(II)，或其药学上可接受的盐、酯或前药：这些化合物抑制、预防或治疗异常细胞增殖和/或病毒感染，特别是HIV、HCV或HBV。因此，本发明的化合物干扰病毒的复制周期，同时也可用作抗病毒剂，或干扰宿主细胞的生化过程，同时也可用作抗增殖剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有病毒感染和/或细胞增殖的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的病毒感染和/或细胞增殖的方法。本发明涉及上述新型抗病毒/抗增殖化合物，包括含有这些化合物的药物组合物，以及用于治疗或预防受试者的病毒感染的方法。
• Isolation, Synthesis, and Characterization of Impurities and Degradants from the Clofarabine Process
  作者：Bruce G. Anderson、William E. Bauta、William R. Cantrell, Jr.、Tracy Engles、Dennis P. Lovett

  DOI：10.1021/op800182x

  日期：2008.11.21

  process impurities and their subsequent isolation, synthesis, and characterization is described. Two isomeric process impurities resulting from N6-attachment of a fluoroarabinose to clofarabine were found. Clofarabine’s base degradation products, which were different from the process impurities, were also synthesized and characterized. These compounds resulted from modifications to the sugar moiety, the

  介绍了氯法拉滨工艺杂质的鉴定及其随后的分离，合成和表征。发现了由氟代阿拉伯糖的N 6-附着至氯法拉滨产生的两种异构过程杂质。还合成并表征了与工艺杂质不同的氯法拉滨的碱降解产物。这些化合物是由糖部分，嘌呤环或两者的修饰产生的。提供了用于形成各种工艺杂质和降解产物的机械原理。
• Synthesis and biological activity of 2'-fluoro-2-halo derivatives of 9-.beta.-D-arabinofuranosyladenine
  作者：John A. Montgomery、Anita T. Shortnacy-Fowler、Sarah D. Clayton、James M. Riordan、John A. Secrist

  DOI：10.1021/jm00080a029

  日期：1992.1

  The synthesis of 2-halo-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenines (4b and 4d) by coupling the 2,6-dihalopurine with 3-acetyl-5-benzoyl-2-deoxy-2-fluoro-D-arabinofuranosyl bromide (2) followed by replacement of the 6-halogen with concomitant removal of the acyl blocking groups is described. 2-Fluoroadenine derivative 4g had to be prepared by the diazotization-fluorination of 2-aminoadenine

  通过将2,6-二卤代嘌呤与3-乙酰基-5-苯甲酰基-2-脱氧偶合，合成2-卤代9-（2-脱氧-2-氟-β-D-阿拉伯呋喃糖基）ni啶（4b和4d）描述了-2-氟-D-阿拉伯呋喃糖基溴化物（2），然后取代6-卤素并同时去除了酰基保护基团。必须通过2-氨基腺嘌呤核苷4e的重氮化-氟化来制备2-氟鸟嘌呤衍生物4g。所有三种核苷均能使接种P388白血病的小鼠的寿命延长。当在白血病细胞植入后第1、5和9天每3h x 8给予化合物时，可获得最佳结果。通过4f脱乙酰基化并在4h脱氧后再去除5a的苯甲酰基制得的2'，3'-二脱氧核苷5b在细胞培养中对HIV具有轻微的活性。
• 2'-Fluoronucleoside phosphonates as antiviral agents
  申请人：Shi Junxing

  公开号：US20070225249A1

  公开（公告）日：2007-09-27

  The present invention includes compounds and compositions of R -2′-fluoronucleoside phosphonates, as well as methods to treat HIV, HBV, HCV or abnormal cellular proliferation comprising administering said compounds or compositions.

  本发明涉及R-2'-氟核苷酸膦酸酯化合物和组合物，以及使用该化合物或组合物治疗HIV、HBV、HCV或异常细胞增殖的方法。